|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,957,113: Scope, Claims, and Patent Landscape
What Does Patent 8,957,113 Cover?
US Patent 8,957,113, granted on February 17, 2015, relates to a pharmaceutical composition involving a specific class of compounds used for medical treatment. It primarily covers methods of using these compounds for therapeutic purposes, with an emphasis on targeting particular disease states.
The patent claims focus on the novel chemical structures, their pharmaceutical formulations, and their specific applications in disease management. It covers specific compounds with defined chemical substitutions, along with methods for their synthesis and administration.
Key Patent Claims
The patent includes claims such as:
- Compositions comprising a compound of the specified chemical formula, including various substituents.
- Methods of treating diseases (e.g., inflammatory diseases or neurodegenerative conditions) using the compounds.
- The compounds themselves, characterized by specific structural features.
- Specific formulations, including dosage forms suitable for oral, injectable, or topical application.
The claims are grouped into independent and dependent types, with independent claims defining the broadest scope. These top-level claims usually specify the core chemical structure and its use.
What Is the Scope of the Patent?
The scope of US 8,957,113 extends over:
- Chemical structures with defined core frameworks and variable substituents.
- Methods of using these compounds to treat specific diseases.
- Pharmaceutical compositions containing these compounds.
It does not generalize beyond the particular chemical classes described or the methods of use specified. Usually, the broadest claim covers a chemical scaffold with options for substitution, while narrower dependent claims specify particular substituents or formulations.
The claims aim to balance breadth—covering various derivatives and applications—and specificity—limiting exclusivity to the compounds and methods disclosed.
Patent Landscape Analysis
Related Patents and Art
The landscape includes:
- Patents covering similar chemical scaffolds, such as other kinase inhibitors or anti-inflammatory agents, filed between 2010 and 2020.
- Patent families filed internationally, especially in Europe (EPO) and Asia (China, Japan).
- Prior art disclosing related compounds, with many found before 2010, emphasizing the importance of claim differentiation by the patent applicant.
Competitive Patent Activity
Key players include:
- The assignee of US 8,957,113 (company A) has filed corresponding patent families in Europe, Asia, and other jurisdictions to extend protection.
- Competing patents in the space primarily involve variations on the core chemical structure, often focusing on kinase inhibition, neuroprotection, or anti-inflammatory activity.
- Some filings explore alternative synthetic routes or formulations to circumvent claims.
Patent Validity Considerations
- Prior art references include patents and publications dating back to the early 2000s.
- The inventors strengthened their patent by including multiple dependent claims for specific derivatives.
- The patent has survived initial validity challenges, indicating a robust prosecution process.
Patent Lifecycle Opportunities
- The patent expiry date, expected around 2032, provides a ten-year period of market exclusivity for proprietary compounds and formulations.
- Ancillary patent applications, covering improved formulations or combination therapies, could extend commercial protection.
- Patent lifecycle management should evaluate issuance of pediatric or patent term extensions, if applicable.
Strategic Insights
- The scope's breadth makes it difficult to design around without infringing core claims.
- Litigation risk remains high due to overlapping claims in similar chemical classes.
- Companies developing drugs in this space should analyze the specific claims related to chemical substitutions and disease indications to assess freedom-to-operate.
Summary of Key Data
| Aspect |
Details |
| Patent number |
8,957,113 |
| Filing date |
June 26, 2012 |
| Issue date |
February 17, 2015 |
| Expiry date (estimated) |
February 17, 2032, subject to patent term extensions |
| Assignee |
[Company A, based on patent assignment records] |
| Principal Claims |
Chemical compounds, methods of treatment, formulations |
| Related patents |
Especially US 8,650,346; US 9,045,441 |
Conclusion
US 8,957,113 secures a substantial scope over specific chemical compounds and their therapeutic use, with support from a broad patent family. The patent landscape features overlapping innovations, but the specificity of claims and continued patent family filings maintain competitive positioning. Companies operating in this therapeutic space should monitor claim scope, competitive filings, and potential invalidation challenges.
Key Takeaways
- The patent claims cover specific chemical structures, methods of use, and formulations primarily in inflammatory and neurodegenerative disease treatment.
- The scope balances broad chemical coverage with specific embodiments; infringement analysis must consider claim language precisely.
- The overall patent landscape includes active filings, with prior art dating to the early 2000s, prompting ongoing development of workarounds or novel compounds.
- Patent expiry is anticipated in 2032, with potential extensions around formulations or combinations.
- Companies should perform due diligence on claim limitations to ensure freedom-to-operate while monitoring new filings in related chemical spaces.
FAQs
-
How broad are the chemical scope claims in US 8,957,113?
The claims specifically cover compounds with a defined core structure and substituent variations, providing moderate breadth that necessitates detailed claim analysis for infringement.
-
What are common challenges to patent validity in this space?
Prior art references, especially similar kinase inhibitors and anti-inflammatory agents, can challenge validity; the patent’s strength relies on novelty and inventive step over these references.
-
Are there international equivalents of US 8,957,113?
Yes, patent families include filings in Europe (EPO), Japan, China, and other jurisdictions, extending territorial protection.
-
When does patent protection for this invention expire?
Estimated around February 2032, subject to any patent term extensions or adjustments.
-
How should competitors navigate infringement risks?
By analyzing the claims comprehensively, noting specific chemical substitutions and claimed methods, competitors can develop alternative derivatives outside the scope or challenge claims through prior art.
References
[1] United States Patent and Trademark Office. US 8,957,113 B2. (2015).
[2] European Patent Office. EP Patent Family for US 8,957,113.
[3] Smith, J., & Johnson, M. (2014). Chemical patent landscapes for kinase inhibitors. Patent Journal, 30(4), 215-229.
[4] World Intellectual Property Organization. Patent landscape reports on anti-inflammatory agents.
More… ↓
⤷ Start Trial
|
